恩华药业(002262.SZ)全资子公司签署安泰坦产品独家商业化许可和合作协议

智通财经02-26

智通财经APP讯，恩华药业(002262.SZ)公告，公司全资子公司江苏恩华和信医药营销有限公司(简称：“恩华和信”)与Teva Pharmaceutical Investments Singapore PTE LTD(简称：“TEVA”)于2024年2月22日签署了安泰坦®(氘丁苯那嗪片)(简称：“安泰坦”或“许可产品”)产品独家商业化许可和合作协议，协议期限自2024年2月22日至2029年2...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2414048703?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-02-26 08:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2414048703","market":"hk","top_or_hot":-1,"title":"恩华药业(002262.SZ)全资子公司签署安泰坦产品独家商业化许可和合作协议","media":"智通财经","content":"<div>\n<p>智通财经APP讯，恩华药业(002262.SZ)公告，公司全资子公司江苏恩华和信医药营销有限公司(简称：“恩华和信”)与Teva Pharmaceutical Investments Singapore PTE LTD(简称：“TEVA”)于2024年2月22日签署了安泰坦®(氘丁苯那嗪片)(简称：“安泰坦”或“许可产品”)产品独家商业化许可和合作协议，协议期限自2024年2月22日至2029年2...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1076451.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恩华药业(002262.SZ)全资子公司签署安泰坦产品独家商业化许可和合作协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恩华药业(002262.SZ)全资子公司签署安泰坦产品独家商业化许可和合作协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-26 08:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1076451.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，恩华药业(002262.SZ)公告，公司全资子公司江苏恩华和信医药营销有限公司(简称：“恩华和信”)与Teva Pharmaceutical Investments Singapore PTE LTD(简称：“TEVA”)于2024年2月22日签署了安泰坦®(氘丁苯那嗪片)(简称：“安泰坦”或“许可产品”)产品独家商业化许可和合作协议，协议期限自2024年2月22日至2029年2...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1076451.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1076451.html","article_id":"2414048703","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2414048703","pubTimestamp":1708907511,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，恩华药业 公告，公司全资子公司江苏恩华和信医药营销有限公司与Teva Pharmaceutical Investments Singapore PTE LTD于2024年2月22日签署了安泰坦产品独家商业化许可和合作协议，协议期限自2024年2月22日至2029年2月22日。恩华和信获得TEVA安泰坦于中国大陆的独家商业化权益。作为对TEVA或其关联方根据合作协议所授予的权利和许可的对价，恩华和信应向TEVA或其关联方支付3000万美元的许可费。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4550":"红杉资本持仓","TEVA":"梯瓦制药","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4588":"碎股","BK4083":"家庭装潢零售","BK4207":"综合性银行","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4581":"高盛持仓","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","BK4504":"桥水持仓","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0823411888.USD":"法巴消费创新基金 Cap","LU0079474960.USD":"联博美国增长基金A","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","HD":"家得宝","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4584":"避孕概念","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","BK4559":"巴菲特持仓","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4557":"大麻股","TD":"道明银行"},"translate_title":"A wholly-owned subsidiary of Enhua Pharmaceutical (002262. SZ) signed an exclusive commercialization license and cooperation agreement for Antetan products","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TD":1,"HD":1,"TEVA":0.63},"content_text":"智通财经APP讯，恩华药业(002262.SZ)公告，公司全资子公司江苏恩华和信医药营销有限公司(简称：“恩华和信”)与Teva Pharmaceutical Investments Singapore PTE LTD(简称：“TEVA”)于2024年2月22日签署了安泰坦®(氘丁苯那嗪片)(简称：“安泰坦”或“许可产品”)产品独家商业化许可和合作协议，协议期限自2024年2月22日至2029年2月22日。恩华和信获得TEVA安泰坦于中国大陆(简称：“许可区域”)的独家商业化权益。作为对TEVA或其关联方根据合作协议所授予的权利和许可的对价，恩华和信应向TEVA或其关联方支付3000万美元的许可费。据悉，本次交易涉及的安泰坦系美国食品药品监督管理局(FDA)2017年批准的囊泡单胺转运蛋白2(VMAT2)抑制剂，于2020年获得中国国家药品监督管理局批准，用于治疗成人与亨廷顿病(HD)有关的舞蹈病及迟发性运动障碍(TD)，并于当年通过国家医保谈判进入医保目录。在中枢神经领域，通过此次合作，安泰坦将进一步丰富公司中枢神经领域的产品线，在市场推广方面将与公司该领域现有重点品种共享专家网络及临床资源，互相促进，共同发展，形成有效协同。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2414048703"}